Table 1. Patient characteristics, clinicopathological variables, and molecular markers as predictors of biochemical- and clinical failure in prostate cancer patients (n = 535), (univariate analysis; log-rank test) significant P values in bold (threshold ≤ 0.05).

Variable	Patients	BF		CF
	(n)	(200 events)		(56 events)
		5-year EFS (%)	p	10-year EFS (%)	p
Age			0.237		0.038
≤ 65 years	357	77		94
> 65 years	178	70		91
pT-stage			< 0.001		< 0.001
pT2	374	83		97
pT3a	114	61		87
pT3b	47	43		74
Preop PSA			< 0.001		0.029
PSA<10	308	81		95
PSA>10	221	68		89
Missing	6	-		-
Gleason grade			< 0.001		< 0.001
3+3 / Grade group 1	183	83		98
3+4 / Grade group 2	219	77		94
4+3 / Grade group 3	81	70		90
4+4 / Grade group 4	17	58		86
>8 / Grade group 5	35	37		65
Tumor Size			< 0.001		0.002
0-20 mm	250	83		96
>20 mm	285	68		90
PNI			< 0.001		< 0.001
No	401	80		96
Yes	134	60		83
PSM			0.049		0.198
No	249	69		90
Yes	286	81		96
Non-apical PSM			< 0.001		< 0.001
No	381	82		96
Yes	154	57		85
Apical PSM			0.063		0.427
No	325	74		92
Yes	210	77		93
LVI			< 0.001		< 0.001
No	492	77		95
Yes	43	47		69
Surgical proc			0.466		0.308
Retropubic	435	77		92
Perineal	100	68		95
PD-1+ lymphocytes in TS			0.489		0.084
Low	353	74		94
High	43	69		87
Missing	139
PD-L1+ TS cells			0.899		0.680
Low	245	28		92
High	157	74		91
Missing	133
PD-L1+ TE cells			0.078		0.603
Low	166	77		92
High	236	71		92
Missing	133

Abbreviations: BF = biochemical failure; CF = clinical failure; EFS = event free survival in months; LVI = lymphovascular infiltration; p = p value for difference in event free survival with log rank analysis; PD-1 = programmed cell death protein 1; PD-L1 = programmed death-ligand 1; PNI = Perineural infiltration; Preop = preoperative; PSA = Prostate specific antigen; PSM = Positive surgical margin; pT-stage = pathological tumor stage; Proc = procedure; TE = tumor epithelial cells; TS = tumor stromal cells